Citi Downgrades Medivation (MDVN) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/20/2026
- Wall St futures edge higher ahead of this week's megacap earnings
- Oil reverses as Iranian comments interpreted as chance for fresh negotiations
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Medifast launches Trilivy, replacing its Optavia brand
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Adobe has received a takeover approach by a Big Tech company - Betaville
Brean Capital Downgrades Medivation (MDVN) to Hold
August 22, 2016 1:01 PM EDTBrean Capital downgraded Medivation (NASDAQ: MDVN) from Buy to Hold.
For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.
Shares of Medivation closed at $67.16 yesterday.
... MoreWedbush Downgrades Medivation (MDVN) to Neutral
August 22, 2016 1:00 PM EDTWedbush downgraded Medivation (NASDAQ: MDVN) from Outperform to Neutral.
For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.
Shares of Medivation closed at $67.16 yesterday.
... MorePfizer (PFE) to Acquire Medivation (MDVN) in $14B Deal
August 22, 2016 6:45 AM EDTPfizer Inc. (NYSE: PFE) and Medivation, Inc. (Nasdaq: MDVN) announced that they have entered into a definitive merger agreement under which Pfizer will acquire Medivation, a biopharmaceutical company focused on developing and commercializing small molecules for oncology, for $81.50 a share in cash for a total enterprise value of approximately $14 billion. The Boards of Directors of both companies have unanimously approved the merger, which is expected to be immediately accretive to Pfizers Adjusted Diluted EPS upon closing, approximately $0.05 accretive in the first full year after close with... More
